Beta
Odevixibat
medication Under reviewAn ileal bile acid transporter (IBAT) inhibitor used to treat pruritus in patients with progressive familial intrahepatic cholestasis.
Research summary
Scientific evidence for odevixibat centers on phase 3 clinical trials demonstrating reductions in pruritus scores and serum bile acid levels in patients with Alagille syndrome and PFIC, with sustained benefits observed in long-term extensions. While efficacy is consistent across studies, the research is limited to pediatric populations with specific cholestatic diseases, lacking data in healthy adults. No studies involving healthy human subjects were identified, precluding assessment of benefits or risks in this group. Safety profiles indicate mostly mild gastrointestinal effects, but long-term data remain confined to diseased cohorts.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Research
No studies found yet. Request research to discover relevant studies.
Community updates
No updates yet for this supplement.
Be the first to share your experience!